Table 1.

Therapeutic effects of small molecule antagonists of α9α10 nAChRs, α‐Ctxs, and α‐Ctx analogues in neuropathic pain

Ligand	Pain model	Therapeutic effects
RgIA	CCI	Reduced mechanical allodynia and mechanical hyperalgesia; disease‐modifying effectsa , b
	Oxaliplatin‐induced neuropathy	Reduced mechanical allodynia and mechanical hyperalgesia; reduced cold allodynia; disease‐modifying effectsc
RgIA4	Oxaliplatin‐induced neuropathy	Reduced mechanical hyperalgesia; reduced cold allodynia; prolonged effectsd
Vc1.1	CCI	Reduced mechanical allodynia and mechanical hyperalgesia; disease‐modifying effectsb , e
	PSNL	Reduced mechanical allodynia and mechanical hyperalgesiae , f , g
	Streptozotocin‐induced neuropathy	Reduced mechanical allodyniah , i
	CVH	Reduced excitability of nociceptorsj
vc1a	CCI	No effect on mechanical allodyniag; accelerated recovery of sensory nervesh
cVc1.1	CCI	Reduced mechanical allodyniak
[Ser3]Vc1.1(1–8)	VMR	Reduced visceromotor responsel
AuIB	PSNL	Reduced mechanical allodyniaf , g
αO‐GeXIVA	CCI	Reduced mechanical allodyniam , n
ZZ‐204G	CCI	Reduced mechanical hyperalgesiao
	Formalin test	Reduced inflammatory paino
	Tail flick	No effecto
ZZ1‐61c	Vincristine‐induced neuropathy	Reduced mechanical allodynia and mechanical hyperalgesiap

CVP, chronic visceral hypersensitivity; VMR, visceromotor response.

Mechanical allodynia measured with the Von Frey test; mechanical hyperalgesia measured with the paw pressure test.

^aDi Cesare Mannelli et al., 2014.

^bVincler et al., 2006.

^cPacini et al., 2016.

^dRomero et al., 2017.

^eSatkunanathan et al., 2005.

^fNapier et al., 2012.

Klimis et al., 2011.

^gNevin et al., 2007.

^hLivett et al., 2008.

ⁱMcIntosh et al., 2009.

^jCastro et al., 2017.

^kClark et al., 2010.

^lCarstens et al., 2016a.

^mLuo et al., 2015.

ⁿLi et al., 2016.

^oHoltman et al., 2011.

^pWala et al., 2012.